These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33762203)

  • 41. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
    Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
    Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
    Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
    Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
    Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
    Kelly JD; Tan WS; Porta N; Mostafid H; Huddart R; Protheroe A; Bogle R; Blazeby J; Palmer A; Cresswell J; Johnson M; Brough R; Madaan S; Andrews S; Cruickshank C; Burnett S; Maynard L; Hall E;
    Eur Urol; 2019 Apr; 75(4):593-601. PubMed ID: 30279015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
    Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
    Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
    Oddens J; Brausi M; Sylvester R; Bono A; van de Beek C; van Andel G; Gontero P; Hoeltl W; Turkeri L; Marreaud S; Collette S; Oosterlinck W
    Eur Urol; 2013 Mar; 63(3):462-72. PubMed ID: 23141049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
    Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic overview of chemotherapy effects in urothelial bladder cancer.
    Nilsson S; Ragnhammar P; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):371-90. PubMed ID: 11441942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis.
    Pan J; Liu M; Zhou X
    Front Med; 2014 Jun; 8(2):241-9. PubMed ID: 24810644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
    Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ
    Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
    Perlis N; Zlotta AR; Beyene J; Finelli A; Fleshner NE; Kulkarni GS
    Eur Urol; 2013 Sep; 64(3):421-30. PubMed ID: 23830475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials.
    Sari Motlagh R; Mori K; Laukhtina E; Aydh A; Katayama S; Grossmann NC; Mostafai H; Pradere B; Quhal F; Schuettfort VM; Roshandel MR; Karakiewicz PI; Teoh J; Shariat SF; Fajkovic H
    BJU Int; 2021 Sep; 128(3):280-289. PubMed ID: 33683778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.